Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/368"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: Fluoxetine was dosed at 40 mg/day for 11 days. On the morning of the 12th day participants received a final dose of antidepressant followed by a 3-mCi dose of radio-labled erythromycin by IV then, 20 minutes later, a 2 mg dose of alprazolam orally. (See NOTE below)
population: 16 healthy males, non-smokers,
tested for known CYP450 polymorphisms? Yes; "subjects were phenotyped with dextromethorphan prior to entering the study to exclude CYP2D6-poor metabolizers"
ages:18 - 25
description:
Compared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism ( P > 0.05). For nefazodone, a statistically significant inhibition was observed ( P < 0.0005). Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration � versus � time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at aseline. No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested.
NOTE: Although erythromycin is known to inhibit CYP3A4 activity, it is the opinion of DIKB reviewer's, the dose of erythromycin given in this study was too low to have any relevant inhibitory effect on CYP3A4"
|
| dc:creator | |
| dc:date |
"09/22/2009 19:37:07"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ fluoxetine_increases_auc_alprazolam, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1365 }